OBJECTIVES: The present study is to evaluate the expression level of enhancer of zeste homolog 2 (EZH2) and vascular endothelial growth factor (VEGF), and analyze their correlations with clinicopathological characteristics and survival in patients with clear cell renal cell carcinoma (CCRCC). The effect of EZH2 on apoptosis and cell proliferation in 786-O renal cancer cell line is investigated. METHODS: The expression level of EZH2 and VEGF was detected in 185 primary CCRCC patients' tissues using tissue microarray and immunohistochemistry. Small interfering RNA or enhanced green fluorescent protein transfection was employed to investigate the effect of EZH2 inhibition or overexpression on VEGF expression, apoptosis and cell proliferation in 786-O cells using flow cytometry, immunofluorescence microscopy, quantitative real-time reverse-transcription polymerase chain reaction and Western blot analysis. RESULTS: High expression level of EZH2 and VEGF was observed in advanced CCRCC and correlated with the TNM stage (p = 0.013, p = 0.001) and distant metastasis (p = 0.011, p = 0.038), respectively. EZH2 was positively correlated with VEGF in CCRCC tissues (correlation coefficient = 0.850, p < 0.001). Kaplan-Meier survival analysis revealed that patients with positive EZH2 expression had a shorter overall survival time compared to patients with negative EZH2 expression (34.3 vs. 67.2, p < 0.001). In 786-O cells, EZH2 silencing inhibited VEGF expression and cell proliferation while increasing apoptosis (p < 0.001). EZH2 overexpression promoted VEGF expression and cell proliferation while inhibiting apoptosis (p < 0.001). CONCLUSIONS: EZH2 correlates positively with VEGF and associates with adverse clinicopathologic characteristics and shorter survival time in CCRCC patients. EZH2 accelerates antiapoptosis and cell cycle in 786-O cells.
OBJECTIVES: The present study is to evaluate the expression level of enhancer of zeste homolog 2 (EZH2) and vascular endothelial growth factor (VEGF), and analyze their correlations with clinicopathological characteristics and survival in patients with clear cell renal cell carcinoma (CCRCC). The effect of EZH2 on apoptosis and cell proliferation in 786-O renal cancer cell line is investigated. METHODS: The expression level of EZH2 and VEGF was detected in 185 primary CCRCC patients' tissues using tissue microarray and immunohistochemistry. Small interfering RNA or enhanced green fluorescent protein transfection was employed to investigate the effect of EZH2 inhibition or overexpression on VEGF expression, apoptosis and cell proliferation in 786-O cells using flow cytometry, immunofluorescence microscopy, quantitative real-time reverse-transcription polymerase chain reaction and Western blot analysis. RESULTS: High expression level of EZH2 and VEGF was observed in advanced CCRCC and correlated with the TNM stage (p = 0.013, p = 0.001) and distant metastasis (p = 0.011, p = 0.038), respectively. EZH2 was positively correlated with VEGF in CCRCC tissues (correlation coefficient = 0.850, p < 0.001). Kaplan-Meier survival analysis revealed that patients with positive EZH2 expression had a shorter overall survival time compared to patients with negative EZH2 expression (34.3 vs. 67.2, p < 0.001). In 786-O cells, EZH2 silencing inhibited VEGF expression and cell proliferation while increasing apoptosis (p < 0.001). EZH2 overexpression promoted VEGF expression and cell proliferation while inhibiting apoptosis (p < 0.001). CONCLUSIONS:EZH2 correlates positively with VEGF and associates with adverse clinicopathologic characteristics and shorter survival time in CCRCC patients. EZH2 accelerates antiapoptosis and cell cycle in 786-O cells.
Authors: Roland Hubaux; Kelsie L Thu; Bradley P Coe; Calum MacAulay; Stephen Lam; Wan L Lam Journal: J Thorac Oncol Date: 2013-08 Impact factor: 15.609
Authors: Michiel Smits; Shahryar E Mir; R Jonas A Nilsson; Petra M van der Stoop; Johanna M Niers; Victor E Marquez; Jacqueline Cloos; Xandra O Breakefield; Anna M Krichevsky; David P Noske; Bakhos A Tannous; Thomas Würdinger Journal: PLoS One Date: 2011-01-28 Impact factor: 3.240
Authors: Bettina Fussbroich; Nina Wagener; Stephan Macher-Goeppinger; Axel Benner; Maria Fälth; Holger Sültmann; Angela Holzer; Karin Hoppe-Seyler; Felix Hoppe-Seyler Journal: PLoS One Date: 2011-07-13 Impact factor: 3.240
Authors: Ø Fluge; K Gravdal; E Carlsen; B Vonen; K Kjellevold; S Refsum; R Lilleng; T J Eide; T B Halvorsen; K M Tveit; A P Otte; L A Akslen; O Dahl Journal: Br J Cancer Date: 2009-09-22 Impact factor: 7.640
Authors: Jessica Okosun; Csaba Bödör; Jun Wang; Shamzah Araf; Cheng-Yuan Yang; Chenyi Pan; Sören Boller; Davide Cittaro; Monika Bozek; Sameena Iqbal; Janet Matthews; David Wrench; Jacek Marzec; Kiran Tawana; Nikolay Popov; Ciaran O'Riain; Derville O'Shea; Emanuela Carlotti; Andrew Davies; Charles H Lawrie; Andras Matolcsy; Maria Calaminici; Andrew Norton; Richard J Byers; Charles Mein; Elia Stupka; T Andrew Lister; Georg Lenz; Silvia Montoto; John G Gribben; Yuhong Fan; Rudolf Grosschedl; Claude Chelala; Jude Fitzgibbon Journal: Nat Genet Date: 2013-12-22 Impact factor: 38.330
Authors: Julian C Y Ip; Tony C Y Pang; Anthony R Glover; Patsy Soon; Jing Ting Zhao; Stephen Clarke; Bruce G Robinson; Anthony J Gill; Stan B Sidhu Journal: Oncologist Date: 2015-02-05
Authors: Javier C Angulo; Claudia Manini; Jose I López; Angel Pueyo; Begoña Colás; Santiago Ropero Journal: Cancers (Basel) Date: 2021-04-25 Impact factor: 6.639
Authors: Bert Cruys; Brian W Wong; Anna Kuchnio; Dries Verdegem; Anna Rita Cantelmo; Lena-Christin Conradi; Saar Vandekeere; Ann Bouché; Ivo Cornelissen; Stefan Vinckier; Roeland M H Merks; Elisabetta Dejana; Holger Gerhardt; Mieke Dewerchin; Katie Bentley; Peter Carmeliet Journal: Nat Commun Date: 2016-07-20 Impact factor: 14.919